Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Many healthcare professionals will require people to meet the same prescribing criteria as GLP-1 medications for weight loss
Avoid high-fat foods, they delay gastric emptying even more
Free no card required
Primary Supplement Type: Glutathione, Hyaluronic Acid, Vitamin E
While healthcare leaders are stepping up support for women, the link between menopause and metabolic health is often overlooked
